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Background and Purpose: Intracranial atherosclerosis-related large-vessel occlusion
caused by in situ thrombo-occlusion (ICAS-LVO) has been regarded an important reason
for refractoriness to mechanical thrombectomy (MT). To achieve better outcomes for
ICAS-LVO, different endovascular strategies should be explored. We aimed to investigate
an optimal endovascular strategy for ICAS-LVO.
Methods: We retrospectively reviewed three prospective registries of acute stroke
underwent endovascular treatment. Among them, patients with ICAS-LVOwere assigned
to four groups based on their endovascular strategy: (1)MT alone, (2) rescue intracranial
stenting after MT failure (MT-RS), (3) glycoprotein IIb/IIIa inhibitor infusion after MT
failure (MT-GPI), and (4) a combination of MT-RS and MT-GPI (MT-RS+GPI). Baseline
characteristics and outcomes were compared among the groups. To evaluate whether
the endovascular strategy resulted in favorable outcome, multivariable analysis was
also performed.
Results: A total of 184 patients with ICAS-LVO were included. Twenty-four patients
(13.0%) were treated with MT alone, 25 (13.6%) with MT-RS, 84 (45.7%) with
MT-GPI, and 51 (27.7%) with MT-RS+GPI. The MT-RS+GPI group showed the highest
recanalization efficiency (98.0%). Frequency of patent arteries on follow-up (98.0%, p
< 0.001) and favorable outcome (84.3%, p < 0.001) were higher in the MT-RS+GPI
group than other groups. The MT-RS+GPI strategy remained an independent factor for
favorable outcome (odds ratio, 20.4; 95% confidence interval, 1.97–211.4; p = 0.012).
Conclusion: Endovascular strategy was significantly associated with procedural and
clinical outcomes in acute stroke by ICAS-LVO. A combination of RS and GPI infusion
might be an optimal rescue modality when frontline MT fails.
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INTRODUCTION
Intracranial atherosclerosis-related large-vessel occlusion (ICAS-
LVO) caused by in situ thrombo-occlusion is a common etiology
in endovascular treatment (EVT) for acute stroke. ICAS-LVO
was frequently reported in ∼17–30% of patients who underwent
EVT in Asia, although the incidence varied, depending on race
or occlusion site (1). Importantly, mechanical thrombectomy
(MT) techniques, including stent retriever thrombectomy (SRT)
and contact aspiration thrombectomy (CAT), are ineffective
in EVT for acute stroke primarily caused by ICAS-LVO (2–
5). Owing to the refractoriness, the number of device passes
can be increased in ICAS-LVO, which could delay time to
recanalization and also make patient’s prognosis worse (6, 7).
Furthermore, arterial injury can be possible when stent retriever
is indiscriminately applied to ICAS-LVO (8). Stent retriever is
also likely to provoke platelet activation on atheromatous plaque,
leading to reocclusion of partially recanalized artery (3).
To overcome occlusions refractory to treatment, specific
rescue treatments appropriate for ICAS [ICAS-specific
modalities (ISMs)], including intracranial stenting, balloon
angioplasty, and glycoprotein IIb/IIIa inhibitor (GPI) infusion,
can be considered (9–13). In several previous studies, ISMs were
associated with higher possibility of successful recanalization,
shorter time to recanalization, and better patient outcome
(14–18). Although the necessity and feasibility of ISMs have been
widely recognized, a practical endovascular strategy for ICAS-
LVO has not yet been established. Reliable information regarding
which ISM is optimal when the frontline MT fails is lacking. For
example, GPI is an efficient rescue modality for the reocclusive
ICAS-LVO; however, we do not know exactly when we need a
more aggressive modality such as emergent intracranial stenting
after GPI injection. While intracranial stenting may ultimately
offer a successful recanalization, it might not always be the case.
If further intracranial stenting cannot guarantee a successful
recanalization, one may have to reconsider the type of ISMs.
To determine a practical endovascular strategy for ICAS-LVO,
procedural and clinical benefits of each ISM for MT failure
should be investigated. Accordingly, the procedural efficiencies
and clinical outcomes were evaluated in the present study based
on endovascular modality for treatment of acute ICAS-LVO.
METHODS
Participants
Consecutive acute stroke patients with an intracranial LVO of
anterior circulation, who underwent EVT between January 2010
and December 2018 in three comprehensive stroke centers,
were retrospectively reviewed. The intracranial internal carotid
artery and M1 segment of middle cerebral artery were defined
as intracranial large vessels. In the present study, patients who
met the following criteria were selected from the prospective
registry: (1) first endovascular modality was MT (SRT and/or
CAT); (2) age ≥18 years; (3) initial National Institutes of Health
Stroke Scale (NIHSS) score ≥4; (4) presentation to the hospital
within 8 h from stroke onset; patients within 8–12 h were also
considered if they had an Alberta Stroke Program Early CT Score
(ASPECTS)≥7; and (5) premorbidmodified Rankin Scale (mRS)
score ≤2. Patients whose occlusion etiology was ICAS-LVO
were finally included in this study. ICAS-LVO was determined
angiographically. Residual fixed focal stenosis >70% of the
target vessel or occlusion at arterial trunk on digital subtraction
angiography was defined as ICAS-LVO (12, 14). ICAS-LVO was
assessed by two independent neurointerventionalists. The κ-
value for the interrater reliability was 0.91. Discrepant cases were
resolved by consensus.
Endovascular Procedure
All endovascular procedures were performed under local
anesthesia. Conscious sedation was allowed as necessary.
The MT procedures were performed according to common
recommendations and previous reports (9, 19). Rescue
treatments were performed when occlusion was refractory
even after several attempts using the frontline MT device; the
occlusion segment was recanalized with severe stenosis leading to
significant flow limitation, or the occlusion tended to reocclude.
Rescue endovascular modalities included switching to the other
MT modality (SRT to CAT or vice versa), a combination of SRT
and CAT, intra-arterial urokinase infusion, balloon angioplasty,
intracranial stenting, and/or intra-arterial or intravenous GPI
infusion. Selection of the optimal rescue modality depended on
the operator’s judgment. However, when ICAS was suspected as
the cause of LVO, the patient was treated by one of the following
endovascular modalities: (1) intracranial rescue stenting with
or without balloon angioplasty (RS), (2) GPI infusion, or (3)
both modalities. Typically, 5–10mg of abciximab (1–2 mg/min)
or 0.3–1.5mg of tirofiban (0.05 mg/mL concentration with 0.1
mg/min) was used. A sequence of RS and GPI infusion was not
specified. For RS, Solitaire R© (Medtronic, Dublin, Ireland) or
Wingspan R© (Stryker, Kalamazoo, MI, USA) was used. To secure
the stability of arterial patency achieved using RS and/or GPI
infusion, serial delay angiograms were taken for at least 20min
after recanalization was achieved. When significant angiographic
worsening in arterial patency and perfusion were not observed,
the procedure was finished.
Successful recanalization was defined as achieving modified
TICI grade 2b or 3 and no reocclusion observed on delayed
angiograms during the procedure. Dichotomized modified TICI
grades (0–2a vs. 2b−3) were assessed by two independent
neurointerventionalists blinded to clinical information and
follow-up imaging. The κ-value for the interrater reliability was
0.81. All discrepant cases were resolved by consensus.
Postprocedural Antithrombotic Medication
and Follow-Up Examinations
The types and timing of postprocedural antithrombotic
medication were determined by consensus of
neurointerventionalists and stroke neurologists from each
participating center. Although not regulated under specific
protocols, the postprocedural antithrombotic medication was
summarized as follows: (1) no antithrombotic medication until
intracranial hemorrhage was excluded based on brain imaging
on the next day of EVT, (2) administration of single (aspirin
100–300mg or clopidogrel 75mg) or dual oral antiplatelets
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(aspirin 100–300mg with clopidogrel 75mg) immediately after
completion of the EVT procedure, and (3) intravenous infusion
of GPI after completion of the EVT procedure for at least 12 h,
then administration of dual antiplatelets after exclusion of
intracranial hemorrhage based on brain imaging on the next day
of EVT.
Arterial patency of recanalized arteries was evaluated on
follow-upmagnetic resonance angiograms (MRAs) and routinely
performed at 1–7 days after EVT. For some patients who were
medically unstable, CTA was obtained instead of MRA. The
artery was considered patent when significant distal flow was
observed on time-of-flight MRA. The arterial patency on follow-
up was assessed by two independent physicians who were blinded
to final recanalization status and clinical symptoms. The κ-
value for the interrater reliability was 0.89. Discrepant cases were
resolved by consensus.
Clinical Variables
All clinical parameters, including functional outcome, death, and
symptomatic intracerebral hemorrhage (sICH), were collected
from the prospective registries. Functional outcome and death
were assessed based on the mRS score at 3 months after stroke
onset. A favorable outcome was defined as mRS score of 0–2.
The ICH was assessed on CT or MRI scans obtained 24 ± 6 h
after EVT. If the patient’s neurological status worsened, the CT or
MRI scans were obtained anytime to evaluate ICH. The ICH was
defined as symptomatic if the patient’s NIHSS score increased≥4.
Statistical Analyses
Based on the different types of endovascular modalities used to
recanalize ICAS-LVO, endovascular strategies were classified into
four groups: (1) EVT performed only with MT modalities (MT-
alone group); (2) among ISMs, RS performed after MT failure
(MT-RS group); (3) GPI infused afterMT failure (MT-GPI group);
and (4) both RS and GPI infusion performed after MT failure
(MT-RS+GPI group).
First, demographics, risk factors for stroke, procedural details
and outcomes, follow-up arterial patency, and clinical outcomes,
including functional outcome, death, and sICH, were compared
among the groups. Analysis of variance, Kruskal–Wallis test,
χ
2 test, and Fisher exact test were used as appropriate. Second,
to evaluate whether endovascular strategy was independently
associated with functional outcome, a multivariable binary
logistic regression analysis was performed for favorable outcome.
Variables with potential association (p < 0.2 in univariable
analyses) were entered into the multivariable model. For the
univariable analyses, Student t-test, Mann–Whitney U-test, χ2
test, and Fisher exact test were used as appropriate.
A p < 0.05 was considered statistically significant for 95%
confidence interval (CI). All statistical analyses were performed
using SPSS software (version 23; IBM, Armonk, NY, USA).
RESULTS
Among the 1,311 acute stroke patients who met the inclusion
criteria for this study, 192 (14.6%) had ICAS-LVO. After
excluding patients without a 3-month mRS score, 184 patients
(95.8% of all patients with ICAS-LVO; mean age, 67.9 ±
14.0 years; male, 57.6%) were included in the final analysis
(Figure 1). Twenty-four patients (13.0%) were treated only with
MT modality (MT-alone group). ISMs were used in 160 patients
(87.0%): 25 (13.6%) treated with RS (MT-RS group), 84 (45.7%)
with GPI infusion (MT-GPI group), and 51 (27.7%) with both
RS and GPI infusion (MT-RS+GPI group). Age, initial NIHSS
score, and time from stroke onset to puncture differed among
the groups (Table 1). SRT was the predominant frontline MT
modality in all groups, and CAT was used as the frontline
modality in∼30% of patients in MT alone and MT-RS groups.
Recanalization Results Based on
Endovascular Modality
A successful recanalization was achieved in 168 patients [91.3%
(168 of 184)]. MT was successful in only 9.8% (18 of 184) of
all ICAS-LVO patients as a frontline modality (Table 1). Among
the remaining 166 patients who did not experience a successful
recanalization with the frontline MT treatment, 160 were further
treated with ISM. Rescue treatment with ISM was effective in
150 patients [150 of 160 (93.8%); overall recanalization efficiency
of ISM after MT failure]. Recanalization efficiency in the MT-
RS group (80.0%) was significantly lower than in the MT-GPI
(95.2%, p= 0.028) and MT-RS+GPI groups (98.0%, p= 0.013).
Outcomes Based on Endovascular
Modality
On the follow-up examination, 89.9% of recanalized arteries (151
of 168) were patent. The frequency of patent arteries on follow-
up was different based on endovascular modality (p < 0.001;
Table 1) and most frequent in the MT-RS+GPI group (98.0%).
Patent arteries in the MT-RS+GPI group were significantly more
frequent than in theMT alone (70.8%, p= 0.001), MT-RS (56.0%,
p < 0.001), and MT-GPI groups (83.3%, p = 0.009; Figure 2A).
The frequency of patent arteries on follow-up in the MT-RS
group was significantly lower than in the MT-GPI group (p =
0.004) and not significantly different from the MT-alone group.
Functional outcome was also different based on endovascular
modality (p < 0.001; Table 1). Favorable outcome was observed
most in the MT-RS+GPI group (84.3%) and the least in the MT-
alone group (29.2%). Furthermore, favorable outcome in theMT-
RS+GPI group was significantly more frequent than inMT alone
(p < 0.001), MT-RS (44.0%, p < 0.001), and MT-GPI groups
(65.5%, p = 0.017; Figure 2B). Favorable outcome in the MT-
GPI group was significantly more frequent than in the MT-alone
group (p = 0.002). However, functional outcomes in the MT-RS
group were not significantly different from the MT-alone group.
Mortality was different based on endovascular modality, which
was highest in the MT-RS group. The sICH did not differ among
the groups.
The type of endovascular modality used for treating ICAS-
LVO was also an independent factor for favorable outcome
compared with using only the MT modality. Multivariable
analysis showed the MT-RS+GPI modality [odds ratio (OR),
20.4; 95% CI, 1.97–211.4; p = 0.012] remained an independent
factor for favorable outcomes, in addition to younger age,
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FIGURE 1 | Patient selection flow and grouping. EVT, endovascular treatment; MT, mechanical thrombectomy; NIHSS, National Institutes of Health Stroke Scale;
mRS, modified Rankin Scale; ICAS-LVO, intracranial atherosclerosis-related large-vessel occlusion; MT-RS, rescue stenting after mechanical thrombectomy failure;
MT-GPI, glycoprotein IIb/IIIa infusion after mechanical thrombectomy failure; MT-RS+GPI, rescue stenting with glycoprotein IIb/IIIa infusion after mechanical
thrombectomy failure.
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TABLE 1 | Clinical and procedural characteristics and outcomes based on endovascular modality for intracranial atherosclerosis-related large-vessel occlusion.
MT alone (n = 24) MT-RS (n = 25) MT-GPI (n = 84) MT-RS+GPI (n = 51) p-Value
Characteristics
Age, years 74.6 (± 11.9) 69.7 (± 15.6) 65.8 (± 13.2) 67.4 (± 14.6) 0.045
Male 11 (45.8) 16 (64.0) 52 (61.9) 27 (52.9) 0.412
Hypertension 18 (75.0) 14 (56.0) 61 (72.6) 34 (66.7) 0.388
Diabetes 8 (33.3) 8 (32.0) 24 (28.6) 13 (25.5) 0.887
Hypercholesterolemia 7 (29.2) 6 (24.0) 25 (29.8) 12 (23.5) 0.849
Smoking 5 (20.8) 6 (24.0) 30 (35.7) 14 (27.5) 0.414
Coronary artery disease 1 (4.2) 1 (4.0) 5 (6.0) 4 (7.8) 0.890
Atrial fibrillation 3 (12.5) 3 (12.0) 10 (11.9) 5 (9.8) 0.680
Initial NIHSS score 15.5 [11.8; 19.3] 17.0 [15.5; 18.0] 12.0 [7.0; 15.0] 15.5 [12.5; 17.0] <0.001
Occlusion site 0.403
Internal carotid artery 9 (37.5) 5 (20.0) 18 (21.4) 13 (25.5)
Middle cerebral artery 15 (62.5) 20 (80.0) 66 (78.6) 38 (74.5)
ASPECTS 7.5 [6, 9] 8 [7, 9] 8 [7,8] 8 [7,9] 0.174
Use of IV tPA 11 (45.8) 5 (20.0) 25 (29.8) 22 (43.1) 0.101
Frontline MT modality 0.003
Stent retriever 17 (70.8) 18 (72.0) 78 (92.9) 47 (92.2)
Contact aspiration 7 (29.2) 7 (28.0) 6 (7.1) 4 (7.8)
No. of MT passes 2.9 (± 1.5) 3.2 (± 2.0) 2.6 (± 1.7) 2.4 (± 1.1) 0.186
Time of onset to puncture, min 290 [183; 412] 259 [222; 375] 488 [211; 922] 290 [240; 444] 0.005
Total procedure time, min 66 [53; 93] 95 [90; 99] 133 [83; 156] 144 [104; 166] 0.035
Post-procedural antithrombotics <0.001
None 18 (75.0) 17 (68.0) 10 (11.9) 7 (13.7)
Oral antiplatelets immediately after procedure 6 (25.0) 7 (28.0) 1 (1.2) 0 (0.0)
IV GPI infusion followed by oral antiplatelets 0 (0.0) 1 (4.0) 73 (86.9) 44 (86.3)
Outcome
Recanalization
Successful recanalization 18 (75.0) 20 (80.0) 80 (95.2) 50 (98.0) 0.001
Patent artery on follow-up 17 (70.8) 14 (56.0) 70 (83.3) 50 (98.0) <0.001
Favorable outcome 7 (29.2) 11 (44.0) 55 (65.5) 43 (84.3) <0.001
Symptomatic ICH 2 (8.3) 2 (8.0) 2 (2.4) 1 (2.0) 0.323
Mortality 3 (12.5) 5 (20.0) 2 (2.4) 1 (2.0) 0.003
MT,mechanical thrombectomy; MT-RS, rescue stenting after mechanical thrombectomy failure; MT-GPI, glycoprotein IIb/IIIa infusion after mechanical thrombectomy failure; MT-RS+GPI,
rescue stenting with glycoprotein IIb/IIIa infusion after mechanical thrombectomy failure; ASPECTS, Alberta Stroke Program Early Computed Tomography Score; IV tPA, intravenous
tissue plasminogen activator; ICH, intracerebral hemorrhage; NIHSS, National Institutes of Health Stroke Scale.
Values in parentheses represent the standard deviation or the number of patients (%). Brackets represent first and third quartiles.
low initial NIHSS score, lower number of MT device passes,
successful recanalization, patent artery on follow-up, and use
of intravenous infusion of GPI followed by oral antiplatelets
(Table 2).
DISCUSSION
In this study, frontline MT was not very effective in ICAS-
LVO and resulted in <10% of successful recanalization
rate. For patients who experienced failed frontline MT
modality, successful recanalization was achieved in ∼94%
of patients treated with ISM. Recanalization efficiency
using a combination of RS and GPI infusion was relatively
higher than with other ISMs. Among ISMs, a combination
of RS and GPI infusion resulted in significantly more
patent arteries on follow-up and significantly more
favorable outcomes, which was an independent factor for
favorable outcome.
In several previous reports, conventional MT modalities were
shown to be ineffective for ICAS-LVO; thus, alternative or special
strategies for ICAS-LVO are necessary for better EVT outcomes
(9–12, 20). Based on a small number of retrospective studies in
which the procedural details and outcomes were analyzed, most
rescuemodalities for ICAS-LVO included immediate intracranial
stenting, percutaneous balloon angioplasty, GPI infusion, and
combinations of the modalities (referred to as ISMs) (3–5,
13, 14, 21–23). The necessity of ISMs in EVT for ICAS-LVO
is generally recognized; however, unfortunately, the optimal
ISM remains unknown. In clinical practice, one type of ISM
should be chosen after frontline MT device fails. To make
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FIGURE 2 | Frequency of (A) patent artery on follow-up and (B) favorable outcome based on endovascular modality. MT-RS, rescue stenting after mechanical
thrombectomy failure; MT-GPI, glycoprotein IIb/IIIa infusion after mechanical thrombectomy failure; MT-RS+GPI, rescue stenting with glycoprotein IIb/IIIa infusion after
mechanical thrombectomy failure. *Significantly different between groups.
the best decision, many factors should be considered including
which ISM provides a greater possibility to obtain a successful
recanalization, whether the recanalized target artery will be
well-maintained (or patent) after the endovascular procedure,
whether the chosen ISM will cause intracranial hemorrhage,
and whether patient’s clinical outcome will be guaranteed when
the specific ISM is used. If more information regarding these
factors is known, the decision would likely be easier and
more rational.
From a strategic viewpoint, the results from this study
indicated that RS alone was not appropriate as the rescue
endovascular modality. RS alone performed after frontline MT
failure (MT-RS group) was not significantly more beneficial
regarding arterial patency on follow-up and functional outcome.
In addition, patients in the MT-RS group showed the lowest
recanalization efficiency among ISMs, and mortality was rather
high. Conversely, several beneficial effects were observed when
using a combination of RS and GPI infusion after MT failure
(MT-RS+GPI group) such as recanalization efficiency, follow-
up arterial patency, and favorable outcome. Approximately 98%
of patients had a successful recanalization with the combination
of RS and GPI infusion. Patent artery on follow-up and
favorable outcome were significantly more frequent in the MT-
RS+GPI group. Furthermore, use of a combination of RS
and IA GPI infusion was an independent factor for favorable
outcome. Unlike common anxiety regarding hemorrhagic risk,
GPI infusion was not associated with sICH development, which
is in agreement with the results from previous studies (22–
25). Because successful recanalization and patent artery on
follow-up were significant factors affecting favorable outcome,
a combination of RS and GPI infusion might result in a
better patient clinical outcome due to higher recanalization
efficiency and more patent arteries observed on follow-up. In
fact, delayed reocclusion after EVT was highly associated with
poor functional outcome, which was represented by a quite low
OR for favorable outcome (0.035; 95% CI, 0.005–0.243) (26).
According to a recent large registry, worsening of arterial patency
was significantly associated with all kinds of negative clinical
outcomes including early neurological deterioration, short- and
long-term mortality, and poor functional status (OR, 5.37; 95%
CI, 2.70–8.49) (27).
Although favorable outcome in the MT-GPI group was not
comparable with the MT-RS+GPI group (the absolute difference
was∼20%), patients in the MT-GPI group experienced relatively
good recanalization efficiency and follow-up arterial patency. On
multivariable analysis, the OR in the MT-GPI group showed
a tendency for a favorable outcome, although not significantly.
Compared with the MT-RS group, patients in the MT-GPI group
had better recanalization efficiency, follow-up arterial patency,
and more favorable outcome. Therefore, GPI infusion may play a
role in MT failure. To examine the role of GPI infusion after MT
failure, further prospective studies are necessary.
The MT-RS+GPI group showed a much higher rate
of favorable outcome than expected in general. Although
this study did not focus on the specific factors for the
remarkable clinical outcome in the MT-RS+GPI group, we
think that patent artery on follow-up, active and immediate
administration of postprocedural antithrombotics, or a kind
of bias such as the selection of a smaller lesion for further
use of ISM might affect the outstanding clinical outcome.
However, interpretation should be cautious as the rate
of favorable outcome in the MT-RS+GPI group was not
statistically different from that in the MT-GPI group in
multiple comparisons.
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TABLE 2 | Factors associated with favorable outcome.
Univariable Multivariable
Favorable outcome (n = 116) Unfavorable outcome (n = 68) p-value Odds ratio* (95% CI) p-value
Age, years 64.2 (± 14.8) 74.1 (± 9.9) <0.001 0.95 (0.91–0.99) 0.018
Male 76 (65.5) 30 (44.1) 0.005 0.79 (0.30–2.08) 0.636
Hypertension 78 (67.2) 49 (72.1) 0.514
Diabetes 28 (24.1) 25 (36.8) 0.091 0.69 (0.24–1.98) 0.488
Hypercholesterolemia 28 (24.1) 22 (32.4) 0.235
Smoking 44 (37.9) 11 (16.2) 0.002 3.19 (0.97–10.5) 0.056
Coronary artery disease 5 (4.3) 6 (8.8) 0.334
Atrial fibrillation 10 (8.6) 11 (16.2) 0.150 0.45 (0.11–1.88) 0.275
Initial NIHSS score 13.0 [8.0; 16.0] 16.0 [12.0; 20.0] <0.001 0.90 (0.82–0.98) 0.017
Occlusion site 0.903
Internal carotid artery 28 (24.1) 17 (25.0)
Middle cerebral artery 88 (75.9) 51 (75.0)
Use of IV tPA 45 (38.8) 18 (26.5) 0.108 1.69 (0.62–4.66) 0.308
Time of onset to puncture, min 320 [239; 609] 290 [202; 710] 0.631
Total procedure time, min 94 [60; 157] 104 [84; 147] 0.781
Frontline MT modality 0.024
Stent retriever 106 (91.4) 54 (79.4) Reference
Contact aspiration 10 (8.6) 14 (20.6) 0.71 (0.15–3.30) 0.667
No. of MT passes 2.2 (± 1.0) 3.5 (± 2.1) <0.001 0.47 (0.31–0.71) <0.001
Endovascular modalities <0.001
MT alone 7 (6.0) 17 (25.0) Reference
MT-RS 11 (9.5) 14 (20.6) 1.41 (0.07–27.9) 0.822
MT-GPI 55 (47.4) 29 (42.6) 3.21 (0.44–23.5) 0.250
MT-RS+GPI 43 (37.1) 8 (11.8) 20.4 (1.97–211.4) 0.012
Successful recanalization 113 (97.4) 55 (80.9) <0.001 8.48 (1.01–71.8) 0.049
Patent artery on follow-up 109 (94.0) 42 (61.8) <0.001 14.1 (2.05–97.4) 0.007
Postprocedural antithrombotics <0.001
None 18 (15.5) 34 (50.0) Reference
Oral antiplatelets immediately after procedure 8 (6.9) 6 (8.8) 1.62 (0.26–9.96) 0.603
IV GPI infusion followed by oral antiplatelets 90 (77.6) 28 (41.2) 22.8 (1.09–475.9) 0.044
IV tPA, intravenous tissue plasminogen activator; MT, mechanical thrombectomy; MT-RS, rescue stenting after mechanical thrombectomy failure; MT-GPI, glycoprotein IIb/IIIa infusion
after mechanical thrombectomy failure; MT-RS+GPI, rescue stenting with glycoprotein IIb/IIIa infusion after mechanical thrombectomy failure; IV GPI, intravenous glycoprotein IIb/IIIa
inhibitor; NIHSS, National Institutes of Health Stroke Scale.
Values in parentheses represent the standard deviation or the number of patients (%). Brackets represent first and third quartiles.
*Odds ratio for favorable outcome.
This study had several limitations. First, because of the
retrospective nature of this study, procedural decisions were not
regulated under a specific protocol. The timing of frontline MT
failure was determined according to operators’ best judgment.
Thus, successful recanalization using the frontline MT procedure
might have been underestimated. However, the mean number
of MT passes in all groups was not significantly different. More
importantly, themain focus in this study was rescue endovascular
modalities specific to ICAS-LVO, not MT failure. Second, the
choice of ISM may be biased. Hemorrhagic risk is the most
common consideration when using ISM. Many physicians are
concerned that GPI infusion or postprocedural antithrombotics
after emergent stenting elicit intracranial bleeding. Therefore, the
use of ISMmay be biased in patients with less risk of hemorrhagic
complications. A few clinical factors relevant to hemorrhagic risk,
such as a lesion size, might also affect the choice of ISM. However,
lesion sizes representing initial ASPECTS were not significantly
different between groups in this study. Moreover, the focus of
this study was on the type of ISM and not on whether to use
ISM itself; all types of ISM used in this study were thought
equivalent, at least when hemorrhage was considered. Third, the
sequence of GPI infusion and RS was not specified in this study.
One might first consider using an easier or pharmacologic one
and thus conduct an escalating method—GPI infusion first, then
RS if GPI fails. In other cases, GPI can be infused after RS.
However, this study focused only on the type of further ISM, but
not on its sequence. Thus, we did not distinguish the different
sequences of combination. A prospective study is necessary
to verify the treatment effectiveness according to its sequence.
Fourth, this study was conducted in an Asian country, where
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ICAS is more prevalent than in Western countries. However,
ICAS is also an important issue for Hispanic and African
populations. Furthermore, overcoming refractoriness to modern
MT techniques should be discussed regardless of patient’s race.
Consequently, more specific improvements to the endovascular
strategy for ICAS-LVO are necessary. Evaluating and comparing
procedural and clinical outcomes based on the types of rescue
modalities would be of great importance in the field of EVT for
acute stroke.
CONCLUSIONS
Rescue endovascular strategy after MT failure was significantly
associated with procedural and clinical outcomes in acute
stroke caused by ICAS-LVO. Use of a combination of RS
and GPI infusion showed the highest rate of recanalization
efficiency, patent arteries on follow-up, and favorable outcome. A
combination of RS and GPI infusion might be an optimal rescue
modality when frontline MT fails in EVT of ICAS-LVO.
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